Vanguard Capital Management’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.7M Buy
4,496,086
+50,550
+1% +$131K ﹤0.01% 2718
2026
Q2
$12M Buy
4,445,536
+253,473
+6% +$469K ﹤0.01% 2712
2026
Q1
$5.03M Buy
+4,192,063
New +$5.1M ﹤0.01% 3057

Other funds holding FATE

Vanguard Capital Management's FATE Position: Q3 2026 in Review

Vanguard Capital Management increased its Fate Therapeutics (FATE) stake by 1.1% in Q3 2026, buying an estimated $131K and bringing the position to 4,496,086 shares worth $10.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2718.

Vanguard Capital Management first reported a position in FATE in Q1 2026 and has held it in 3 quarters since. The position peaked at $12M in Q2 2026. 101 funds tracked by Wall St. Rank hold FATE as of Q3 2026.

  • Vanguard Capital Management held 4,496,086 shares of Fate Therapeutics worth $10.7M as of Q3 2026.
  • Vanguard Capital Management bought 50,550 Fate Therapeutics shares in Q3 2026, an estimated $131K.
  • Fate Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2718 holding.
  • Vanguard Capital Management first reported a position in Fate Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Fate Therapeutics position peaked at $12M in Q2 2026.
  • 101 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.